These include biological substances paired with a medical device, which may require different regulatory standards.

Use guidance documents such as the FDA’s Combination Products guidance to make appropriate assessments and documentation adjustments for your legacy products. This includes any specific information addressing the classification changes and how these may affect the pathways for market approval and surveillance.

Documentation should include:

• Regulatory classification determination forms or reports
• A rationale for classification, incorporating any historical approvals
• Supporting data or clinical evidence

Moving beyond classification, evaluate how the regulatory requirements evolve with the implementation of IVDR and MDR. This evaluation includes gauging potential impacts on clinical safety requirements, post-market surveillance plans, and overall market access strategies.

Step 2: Identify Documentation Updates for Dossier Preparedness

With the revised deadlines for implementing IVDR and MDR, stakeholders need to focus on updating the technical documentation and regulatory dossiers for their legacy combination products. This ensures consistency with new regulations and maintains compliance.

Key documentation elements include:

• Technical Files: Ensure your technical files align with IVDR and MDR requirements including the unique device identifier (UDI) regulations, risk management documentation, and performance evaluation data.
• Clinical Evaluation Reports (CERs): Reports should undergo rigorous reviews to verify compliance with the new regulations while considering any updated clinical data that may affect safety and performance claims.
• Quality Management Systems (QMS): Evaluate whether revisions in your QMS are necessary to adhere to enhanced requirements under MDR and IVDR.

Documentation practices that need emphasis are:

• Gathering clinical data on device efficacy and safety
• Following IMDRF guidelines for performance studies
• Updating your regulatory pathway flows to reflect additional requirements

It’s recommended to conduct an internal audit against the updated regulations to ensure all required documents are in place, complete with timelines for updates and reassessments.

Step 3: Implement a Change Control Process Reflecting Post-Approval Changes

The introduction of post-approval changes is addressed squarely within the regulations governing legacy combination products. Responding to changes in clinical evidence, manufacturing processes, or quality assurance mechanisms is essential. Implementing a robust change control process ensures organized management of these developments, minimizing risks associated with non-compliance or product recalls.

The following components should be integrated into your change control process:

• Change Request Submissions: Establish clear protocols for change requests impacting both the drug and device components of combination products.
• Impact Assessment: Assess how any alterations could change safety or efficacy profiles.
• Communication Plans: Ensure that all stakeholders, including regulatory agencies and internal teams, are informed of changes and the motivations behind them.

Your change control documentation must include:

• Change request forms that capture essential elements of each change
• Risk analyses clearly detailing how the change could affect product performance
• Approval records showing how the changes were validated through your QMS

Establish and maintain a change control tracking tool that enables you to monitor pending changes, approvals, and their implications on post-market activities like PMS (Post-Market Surveillance).

Step 4: Develop a Comprehensive Post-Market Surveillance Strategy

The IVDR and MDR stipulate a stronger emphasis on post-market surveillance (PMS) for legacy combination products. A robust PMS strategy is fundamental to ongoing compliance and risk management. A well-outlined PMS plan should encompass ongoing data collection, performance monitoring, and incident reporting.

Your PMS strategy should include the following components:

• Data Collection Methods: Utilize methods such as registries, surveys, and user feedback to collect real-world evidence that can help predict and assess product performance over time.
• Adverse Event Reporting: Establish a comprehensive protocol for capturing and reporting complaints effectively. Resource materials should be readily available for stakeholders involved in reporting.
• Periodic Safety Update Reports (PSURs): Ensure compliance with the new requirements for PSURs, conducting regular evaluations of data gathered from PMS.

Your PMS documentation should effectively track:

• Adverse event reports and corrective actions taken
• Product upgrades or changes and their impact on product performance
• Market data that can indicate trends necessitating further investigation

To refine PMS documentation, consider integrating it into your QMS. The synergy will facilitate data analysis and ensure company-wide awareness of product performance metrics.

Step 5: Prepare for Regulatory Submission and Engagement with Competent Authorities

As you revise technical files and enhance your PMS strategy, the next critical phase is preparing for regulatory submission while actively engaging with competent authorities. Maintaining a proactive relationship with agencies such as the FDA or EMA can benefit both compliance and market access.

Follow these action steps to ensure readiness:

• Regulatory Submission Updates: Monitor and incorporate any changes to submission timelines or required documentation stemming from IVDR and MDR compliance.
• Pre-Submission Meetings: Schedule meetings with respective regulatory bodies to address any queries and seek clarification on evolving requirements.
• Continuous Liaison: Establish a point of contact within regulatory agencies for ongoing questions about compliance or product inquiries.

Your submission package should encompass:

• Updated regulatory filings reflective of change controls and PMS data
• Technical documentation indicating compliance with the IVDR and MDR”
• Summary of any significant changes made to products since the last submission

Be prepared with additional documentation that might support your application, such as marketing and promotional considerations or market access strategies and timelines that may have changed due to regulatory updates.

Step 6: Engage in Continued Education and Training for Stakeholders

Finally, the last step involves continuous education and training of all internal stakeholders involved in the lifecycle management of combination products. The transition to IVDR and MDR may introduce complex changes to operational practices, demanding ongoing vigilance and adaptation.

To foster effective learning and compliance:

• Workshops and Training Programs: Regularly conduct training sessions to introduce new regulatory updates and their implications for legacy products.
• Internal Communications: Leverage communication channels to disseminate knowledge regarding changes in compliance expectations.
• External Partnerships: Engage with regulatory consultants or experienced advisors in companion diagnostic regulatory consulting to equip your team with best practices.

Documentation of training activities should include:

• Sign-in sheets and attendance logs
• Feedback from participants to assess the effectiveness of training sessions
• Materials distributed during workshops or training events

In summation, preparing for the impacts of IVDR and MDR updates on legacy combination products requires meticulous planning and execution. Following these steps will facilitate compliance, enhance product reliability, and ensure patient safety across all stages of a product’s lifecycle.